Literature DB >> 25996250

MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.

Inna S Afonina1, Lynn Elton1, Isabelle Carpentier1, Rudi Beyaert1.   

Abstract

The paracaspase MALT1 (mucosa associated lymphoid tissue lymphoma translocation gene 1) is an intracellular signaling protein that plays a key role in innate and adaptive immunity. It is essential for nuclear factor κB (NF-κB) activation and proinflammatory gene expression downstream of several cell surface receptors. MALT1 has been most studied in the context of T-cell receptor-induced NF-κB signaling, supporting T-cell activation and proliferation. In addition, MALT1 hyperactivation is associated with specific subtypes of B-cell lymphoma, where it controls tumor cell proliferation and survival. For a long time, MALT1 was believed to function solely as a scaffold protein, providing a platform for the assembly of other NF-κB signaling proteins. However, this view changed dramatically when MALT1 was found to have proteolytic activity that further fine-tunes signaling. MALT1 proteolytic activity is essential for T-cell activation and lymphomagenesis, suggesting that MALT1 is a promising therapeutic target for the treatment of autoimmune diseases and distinct lymphoma entities. However, interference with MALT1 activity may pose a dangerous threat to the normal functioning of the immune system and should be evaluated with great care. Here we discuss the current knowledge on the scaffold and protease functions of MALT1, including an overview of its substrates and the functional implications of their cleavage.
© 2015 FEBS.

Entities:  

Keywords:  B-cell lymphoma; MALT1; T-cell receptor; cancer; immunity; inflammation; nuclear factor-κB; paracaspase; protease substrates; proteases

Mesh:

Substances:

Year:  2015        PMID: 25996250     DOI: 10.1111/febs.13325

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  36 in total

1.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

Review 2.  API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.

Authors:  Shaun Rosebeck; Megan S Lim; Kojo S J Elenitoba-Johnson; Linda M McAllister-Lucas; Peter C Lucas
Journal:  World J Biol Chem       Date:  2016-02-26

Review 3.  Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome.

Authors:  Inna S Afonina; Zhenyu Zhong; Michael Karin; Rudi Beyaert
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

4.  Inhibition of MALT1 Decreases Neuroinflammation and Pathogenicity of Virulent Rabies Virus in Mice.

Authors:  S Van Gucht; R Beyaert; E Kip; J Staal; H G Tima; L Verstrepen; M Romano; K Lemeire; V Suin; A Hamouda; M Baens; C Libert; M Kalai
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

5.  Differing Requirements for MALT1 Function in Peripheral B Cell Survival and Differentiation.

Authors:  Peishan Lee; Zilu Zhu; Janna Hachmann; Takuya Nojima; Daisuke Kitamura; Guy Salvesen; Robert C Rickert
Journal:  J Immunol       Date:  2016-12-28       Impact factor: 5.422

6.  MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.

Authors:  Linda R Klei; Dong Hu; Robert Panek; Danielle N Alfano; Rachel E Bridwell; Kelly M Bailey; Katherine I Oravecz-Wilson; Vincent J Concel; Emily M Hess; Matthew Van Beek; Phillip C Delekta; Shufang Gu; Simon C Watkins; Adrian T Ting; Peter J Gough; Kevin P Foley; John Bertin; Linda M McAllister-Lucas; Peter C Lucas
Journal:  Cell Rep       Date:  2016-09-27       Impact factor: 9.423

7.  GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.

Authors:  Jing Cheng; Linda R Klei; Nathaniel E Hubel; Ming Zhang; Rebekka Schairer; Lisa M Maurer; Hanna B Klei; Heejae Kang; Vincent J Concel; Phillip C Delekta; Eric V Dang; Michelle A Mintz; Mathijs Baens; Jason G Cyster; Narayanan Parameswaran; Margot Thome; Peter C Lucas; Linda M McAllister-Lucas
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

8.  Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell-Mediated Autoimmunity.

Authors:  Kea Martin; Ratiba Touil; Yeter Kolb; Grozdan Cvijetic; Kiichi Murakami; Laura Israel; Fernanda Duraes; David Buffet; Anton Glück; Satoru Niwa; Marc Bigaud; Tobias Junt; Natasa Zamurovic; Philip Smith; Kathy D McCoy; Pamela S Ohashi; Frédéric Bornancin; Thomas Calzascia
Journal:  J Immunol       Date:  2019-10-28       Impact factor: 5.422

9.  Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach.

Authors:  Aurélie Cleret-Buhot; Yuwei Zhang; Delphine Planas; Jean-Philippe Goulet; Patricia Monteiro; Annie Gosselin; Vanessa Sue Wacleche; Cécile L Tremblay; Mohammad-Ali Jenabian; Jean-Pierre Routy; Mohamed El-Far; Nicolas Chomont; Elias K Haddad; Rafick-Pierre Sekaly; Petronela Ancuta
Journal:  Retrovirology       Date:  2015-12-10       Impact factor: 4.602

10.  Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.

Authors:  Ashleigh Howes; Paul A O'Sullivan; Felix Breyer; Ashavari Ghose; Li Cao; Daniel Krappmann; Anne M Bowcock; Steven C Ley
Journal:  Biochem J       Date:  2016-04-12       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.